- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Gillian M. Russell
News 1 results
Press Release
November 8, 2016
King & Spalding Promotes Eight Counsel in Three Offices
Events 19 results
Speaking Engagement
June 29, 2022
Heather Banuelos, Gillian Russell to Speak at Food and Drug Law Institute’s Introduction to Drug Law and Regulation Course
Webinar
January 25, 2022
2021 Year in Review for Drug and Device Advertising and Promotion – Lessons Learned From FDA Enforcement Letters and Other Key Developments
Speaking Engagement
November 11, 2021
Heather Bañuelos, Gillian Russell to Speak at Food and Drug Law Institute’s Introduction to Drug Law Regulation Conference
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Insights 14 results
Article · Source: Chambers and Partners
March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022
Client Alert
August 6, 2021
FDA Finalizes “Intended Use” Regulations
Article · Source: Chambers and Partners
March 19, 2021
Pharmaceutical Advertising
Client Alert
September 24, 2020
FDA Proposes New Rule Modifying its “Intended Use” Regulations